APD 334 L-Arginine, L-Arginine mono[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indol-3-yl]acetate, L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
Etrasimod arginine is an orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1). Also, it acts as a partial agonist of S1PR4,5. Etrasimod arginine induces reductions in lymphocyte counts in mice. It is acting as immunosuppressive agents.
Orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1)
Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled, lead to irreversible bowel damage and associated comorbidities. Despite the new era of biological therapies, IBDs remain not curative. The treatment purpose is to induce endoscopic remission, reduce the
The Journal of pharmacology and experimental therapeutics, 369(3), 311-317 (2019-03-16)
Lymphocyte trafficking out of secondary lymphoid organs is regulated by concentration gradient-dependent interactions between the membrane-derived lysophospholipid signaling molecule sphingosine 1-phosphate (S1P) and the G-protein-coupled receptor, S1P1 Etrasimod is a novel, next-generation, small-molecule, oral S1P receptor modulator in clinical development
Frontiers in microbiology, 13, 926170-926170 (2022-06-24)
New classes of antibiotics are urgently needed in the fight against multidrug-resistant bacteria. Drug repurposing has emerged as an alternative approach to accelerate antimicrobial research and development. In this study, we screened a library of sphingosine-1-phosphate receptor (S1PR) modulators against
![1,1,2-Trimethylbenz[e]indole ≥98.0% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/296/735/4c0b92e3-1a5f-4c32-8b5b-0b0997c15df4/640/4c0b92e3-1a5f-4c32-8b5b-0b0997c15df4.png)
